Optimizing HER2-Directed Therapy in Early-Stage Breast Cancer

Evanthia Roussos Torres, Roisin Connolly

Research output: Contribution to journalReview article

Abstract

Purpose of Review: HER2-positive early breast cancer has been revolutionized by the development of HER2-directed therapy, which has significantly reduced breast cancer recurrence risk and improved overall survival. Here, we review the available treatment options for this patient population and discuss how we might individualize therapy in the future to optimize the balance of efficacy and toxicity. Recent Findings: The addition of pertuzumab to a trastuzumab-based adjuvant regimen improves pathologic complete response rates and invasive disease-free survival (DFS). Addition of neratinib for patients with high-risk disease also contributes to improved DFS. Summary: Current data supports use of dual HER2-directed therapy in combination with chemotherapy, as well as extended HER2-directed therapy (beyond 1 year), in those with high-risk HER2-positive early breast cancer. Ongoing studies aim to identify biomarkers of response and resistance to standard approaches, as well as identify those who might benefit from a chemotherapy-free treatment paradigm.

Original languageEnglish (US)
Pages (from-to)262-273
Number of pages12
JournalCurrent Breast Cancer Reports
Volume10
Issue number4
DOIs
StatePublished - Dec 1 2018

Fingerprint

Breast Neoplasms
Disease-Free Survival
Therapeutics
Combination Drug Therapy
Biomarkers
Recurrence
Drug Therapy
Survival
Population

Keywords

  • Breast cancer
  • HER2-directed therapy
  • HER2-positive
  • Treatment

ASJC Scopus subject areas

  • Oncology

Cite this

Optimizing HER2-Directed Therapy in Early-Stage Breast Cancer. / Roussos Torres, Evanthia; Connolly, Roisin.

In: Current Breast Cancer Reports, Vol. 10, No. 4, 01.12.2018, p. 262-273.

Research output: Contribution to journalReview article

@article{c6f794da4ced41a69568ce798282f8c0,
title = "Optimizing HER2-Directed Therapy in Early-Stage Breast Cancer",
abstract = "Purpose of Review: HER2-positive early breast cancer has been revolutionized by the development of HER2-directed therapy, which has significantly reduced breast cancer recurrence risk and improved overall survival. Here, we review the available treatment options for this patient population and discuss how we might individualize therapy in the future to optimize the balance of efficacy and toxicity. Recent Findings: The addition of pertuzumab to a trastuzumab-based adjuvant regimen improves pathologic complete response rates and invasive disease-free survival (DFS). Addition of neratinib for patients with high-risk disease also contributes to improved DFS. Summary: Current data supports use of dual HER2-directed therapy in combination with chemotherapy, as well as extended HER2-directed therapy (beyond 1 year), in those with high-risk HER2-positive early breast cancer. Ongoing studies aim to identify biomarkers of response and resistance to standard approaches, as well as identify those who might benefit from a chemotherapy-free treatment paradigm.",
keywords = "Breast cancer, HER2-directed therapy, HER2-positive, Treatment",
author = "{Roussos Torres}, Evanthia and Roisin Connolly",
year = "2018",
month = "12",
day = "1",
doi = "10.1007/s12609-018-0296-5",
language = "English (US)",
volume = "10",
pages = "262--273",
journal = "Current Breast Cancer Reports",
issn = "1943-4588",
publisher = "Current Science, Inc.",
number = "4",

}

TY - JOUR

T1 - Optimizing HER2-Directed Therapy in Early-Stage Breast Cancer

AU - Roussos Torres, Evanthia

AU - Connolly, Roisin

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Purpose of Review: HER2-positive early breast cancer has been revolutionized by the development of HER2-directed therapy, which has significantly reduced breast cancer recurrence risk and improved overall survival. Here, we review the available treatment options for this patient population and discuss how we might individualize therapy in the future to optimize the balance of efficacy and toxicity. Recent Findings: The addition of pertuzumab to a trastuzumab-based adjuvant regimen improves pathologic complete response rates and invasive disease-free survival (DFS). Addition of neratinib for patients with high-risk disease also contributes to improved DFS. Summary: Current data supports use of dual HER2-directed therapy in combination with chemotherapy, as well as extended HER2-directed therapy (beyond 1 year), in those with high-risk HER2-positive early breast cancer. Ongoing studies aim to identify biomarkers of response and resistance to standard approaches, as well as identify those who might benefit from a chemotherapy-free treatment paradigm.

AB - Purpose of Review: HER2-positive early breast cancer has been revolutionized by the development of HER2-directed therapy, which has significantly reduced breast cancer recurrence risk and improved overall survival. Here, we review the available treatment options for this patient population and discuss how we might individualize therapy in the future to optimize the balance of efficacy and toxicity. Recent Findings: The addition of pertuzumab to a trastuzumab-based adjuvant regimen improves pathologic complete response rates and invasive disease-free survival (DFS). Addition of neratinib for patients with high-risk disease also contributes to improved DFS. Summary: Current data supports use of dual HER2-directed therapy in combination with chemotherapy, as well as extended HER2-directed therapy (beyond 1 year), in those with high-risk HER2-positive early breast cancer. Ongoing studies aim to identify biomarkers of response and resistance to standard approaches, as well as identify those who might benefit from a chemotherapy-free treatment paradigm.

KW - Breast cancer

KW - HER2-directed therapy

KW - HER2-positive

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85056339086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056339086&partnerID=8YFLogxK

U2 - 10.1007/s12609-018-0296-5

DO - 10.1007/s12609-018-0296-5

M3 - Review article

AN - SCOPUS:85056339086

VL - 10

SP - 262

EP - 273

JO - Current Breast Cancer Reports

JF - Current Breast Cancer Reports

SN - 1943-4588

IS - 4

ER -